The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2019-08-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-019-11496-z |
| id |
doaj-1fb146a2c258459e81f631757ffb5a98 |
|---|---|
| record_format |
Article |
| spelling |
doaj-1fb146a2c258459e81f631757ffb5a982021-05-11T11:52:46ZengNature Publishing GroupNature Communications2041-17232019-08-0110111210.1038/s41467-019-11496-zThe new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsRyohei Katayama0Bo Gong1Noriko Togashi2Masaya Miyamoto3Masaki Kiga4Shiho Iwasaki5Yasuki Kamai6Yuichi Tominaga7Yasuyuki Takeda8Yoshiko Kagoshima9Yuki Shimizu10Yosuke Seto11Tomoko Oh-hara12Sumie Koike13Naoki Nakao14Hiroyuki Hanzawa15Kengo Watanabe16Satoshi Yoda17Noriko Yanagitani18Aaron N. Hata19Alice T. Shaw20Makoto Nishio21Naoya Fujita22Takeshi Isoyama23Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDaiichi Sankyo Co., LtdDaiichi Sankyo Co., LtdDaiichi Sankyo Co., LtdDaiichi Sankyo Co., LtdDaiichi Sankyo Co., LtdDaiichi Sankyo Co., LtdDaiichi Sankyo Co., LtdDaiichi Sankyo Co., LtdDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDaiichi Sankyo RD Novare Co., LtdDaiichi Sankyo RD Novare Co., LtdDaiichi Sankyo Co., LtdMassachusetts General Hospital Cancer CenterDepartment of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer ResearchMassachusetts General Hospital Cancer CenterMassachusetts General Hospital Cancer CenterDepartment of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer ResearchDivision of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer ResearchDaiichi Sankyo Co., LtdThe treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models.https://doi.org/10.1038/s41467-019-11496-z |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Ryohei Katayama Bo Gong Noriko Togashi Masaya Miyamoto Masaki Kiga Shiho Iwasaki Yasuki Kamai Yuichi Tominaga Yasuyuki Takeda Yoshiko Kagoshima Yuki Shimizu Yosuke Seto Tomoko Oh-hara Sumie Koike Naoki Nakao Hiroyuki Hanzawa Kengo Watanabe Satoshi Yoda Noriko Yanagitani Aaron N. Hata Alice T. Shaw Makoto Nishio Naoya Fujita Takeshi Isoyama |
| spellingShingle |
Ryohei Katayama Bo Gong Noriko Togashi Masaya Miyamoto Masaki Kiga Shiho Iwasaki Yasuki Kamai Yuichi Tominaga Yasuyuki Takeda Yoshiko Kagoshima Yuki Shimizu Yosuke Seto Tomoko Oh-hara Sumie Koike Naoki Nakao Hiroyuki Hanzawa Kengo Watanabe Satoshi Yoda Noriko Yanagitani Aaron N. Hata Alice T. Shaw Makoto Nishio Naoya Fujita Takeshi Isoyama The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models Nature Communications |
| author_facet |
Ryohei Katayama Bo Gong Noriko Togashi Masaya Miyamoto Masaki Kiga Shiho Iwasaki Yasuki Kamai Yuichi Tominaga Yasuyuki Takeda Yoshiko Kagoshima Yuki Shimizu Yosuke Seto Tomoko Oh-hara Sumie Koike Naoki Nakao Hiroyuki Hanzawa Kengo Watanabe Satoshi Yoda Noriko Yanagitani Aaron N. Hata Alice T. Shaw Makoto Nishio Naoya Fujita Takeshi Isoyama |
| author_sort |
Ryohei Katayama |
| title |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_short |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_full |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_fullStr |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_full_unstemmed |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models |
| title_sort |
new-generation selective ros1/ntrk inhibitor ds-6051b overcomes crizotinib resistant ros1-g2032r mutation in preclinical models |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2019-08-01 |
| description |
The treatment of ROS1-rearranged non-small cell lung cancer with the TKI crizotinib is limited due to the emergence of resistance. Here, the authors develop a new ROS1/NTRK inhibitor, DS-6051b, which overcomes crizotinib resistance in preclinical models. |
| url |
https://doi.org/10.1038/s41467-019-11496-z |
| work_keys_str_mv |
AT ryoheikatayama thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT bogong thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikotogashi thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masayamiyamoto thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masakikiga thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT shihoiwasaki thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasukikamai thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yuichitominaga thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasuyukitakeda thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yoshikokagoshima thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yukishimizu thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yosukeseto thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT tomokoohhara thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT sumiekoike thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naokinakao thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT hiroyukihanzawa thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT kengowatanabe thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT satoshiyoda thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikoyanagitani thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT aaronnhata thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT alicetshaw thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT makotonishio thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naoyafujita thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT takeshiisoyama thenewgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT ryoheikatayama newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT bogong newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikotogashi newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masayamiyamoto newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT masakikiga newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT shihoiwasaki newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasukikamai newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yuichitominaga newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yasuyukitakeda newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yoshikokagoshima newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yukishimizu newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT yosukeseto newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT tomokoohhara newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT sumiekoike newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naokinakao newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT hiroyukihanzawa newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT kengowatanabe newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT satoshiyoda newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT norikoyanagitani newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT aaronnhata newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT alicetshaw newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT makotonishio newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT naoyafujita newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels AT takeshiisoyama newgenerationselectiveros1ntrkinhibitords6051bovercomescrizotinibresistantros1g2032rmutationinpreclinicalmodels |
| _version_ |
1721445814632448000 |